当前位置: X-MOL 学术Drug Des. Dev. Ther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Evolving Role of Silodosin for the Treatment of Urological Disorders – A Narrative Review
Drug Design, Development and Therapy ( IF 4.8 ) Pub Date : 2022-08-26 , DOI: 10.2147/dddt.s373659
Luo Jindan 1 , Wang Xiao 1 , Xie Liping 1
Affiliation  

Abstract: Use of α-androgenic receptor blockers remains a mainstay therapeutic approach for the treatment of urological diseases. Silodosin is recommended over other α-blockers for the treatment of lower urinary tract symptoms (LUTS) and benign prostate hyperplasia (BPH), due to its high α1A uroselectivity. Current research data suggest that silodosin is efficacious in the management of various urological diseases. Thus, we herein review the current evidence of silodosin related to its efficacy and tolerability and appraise the available literature that might ultimately aid in management of various urological conditions at routine clinical practice. Literature reveals that silodosin is beneficial in improving nocturia events related to LUTS/BPH. Silodosin exerts effect on relaxing muscles involved in detrusor obstruction, therefore prolonging the need for patients undergoing invasive surgery. Silodosin treatment, either as a monotherapy or combination, significantly improves International Prostate Symptom Score (IPSS) including both storage and voiding symptoms in patients with BPH/LUTS. Patients on other treatment therapies such as phosphodiesterase 5 inhibitors or other α-blockers are well managed with this drug. Steadily, silodosin has proved beneficial in the treatment of other urological disorders such as chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), overactive bladder/acute urinary retention (AUR), premature ejaculation (PE), and prostate cancer post brachytherapy-induced progression. In patients with distal ureteral stones, silodosin treatment is beneficial in decreasing stone expulsion time without affecting stone expulsion rate or analgesic need. Moreover, there were significant improvements in intravaginal ejaculation latency time, quality of life scores, and decrease in PE profile among patients with PE. Silodosin has also demonstrated promising results in increasing the likelihood of successful trial without catheter in patients with AUR and those taking antihypertensive drugs. Reports from Phase II studies have shown promising role of silodosin in the treatment of CP/CPPS as well as facilitating ureteral stone passage. From the robust data in this review, further silodosin treatment strategies in the management of different urological conditions need to be focused on.

Keywords: efficacy, benign prostate hyperplasia, ureteral calculi, prostatitis, silodosin, urological


中文翻译:

西洛多辛在治疗泌尿系统疾病中的作用不断变化——叙述性回顾

摘要:使用α-雄激素受体阻滞剂仍然是治疗泌尿系统疾病的主要治疗方法。由于其高α1A,西洛多辛被推荐用于治疗下尿路症状(LUTS)和良性前列腺增生(BPH),而不是其他α受体阻滞剂尿路选择性。目前的研究数据表明,西洛多辛可有效治疗各种泌尿系统疾病。因此,我们在此回顾了西洛多辛与其疗效和耐受性相关的当前证据,并评估了可能最终有助于在常规临床实践中管理各种泌尿系统疾病的现有文献。文献表明,西洛多辛有助于改善与 LUTS/BPH 相关的夜尿症事件。西洛多辛可以放松参与逼尿肌阻塞的肌肉,因此延长了对接受侵入性手术的患者的需求。西洛多辛治疗,无论是作为单一疗法还是联合疗法,都显着改善了国际前列腺症状评分 (IPSS),包括 BPH/LUTS 患者的储存和排尿症状。使用其他治疗疗法(例如磷酸二酯酶 5 抑制剂或其他 α 受体阻滞剂)的患者可以使用这种药物得到很好的治疗。事实证明,西洛多辛对治疗其他泌尿系统疾病有益,例如慢性前列腺炎/慢性盆腔疼痛综合征 (CP/CPPS)、膀胱过度活动症/急性尿潴留 (AUR)、早泄 (PE) 和近距离放射治疗后的前列腺癌。诱发进展。对于远端输尿管结石患者,西洛多辛治疗有利于减少结石排出时间,而不影响结石排出率或镇痛需求。此外,PE 患者的阴道内射精潜伏期、生活质量评分和 PE 特征降低有显着改善。西洛多辛在增加 AUR 患者和服用抗高血压药物的患者无导管试验成功的可能性方面也显示出可喜的结果。来自 II 期研究的报告表明,西洛多辛在治疗 CP/CPPS 以及促进输尿管结石通过方面具有良好的作用。从本次审查中的可靠数据来看,需要关注在不同泌尿系统疾病管理中进一步的西洛多辛治疗策略。

Keywords:疗效, 良性前列腺增生, 输尿管结石, 前列腺炎, 西洛多辛, 泌尿外科
更新日期:2022-08-26
down
wechat
bug